Sun Pharmaceutical Industries gets a breather; a sign of relief after the US Food and Drug Administration (US FDA) closed the inspection and gave a clean chit to their Dadra unit.
In an interview to CNBC-TV18, Amey Chalke, Research Analyst at HDFC Securities spoke about the same and shared his views on Lupin as well.
The clean chit is sentimentally positive. However, we have not done any changes in our estimates because many key product approvals are stuck in Halol facility rather than the Dadra unit, said Chalke.
“We have neutral rating on the stock. We had downgraded the stock two quarters back. We will remain neutral until we get good visibility on Halol resolution and also if there is a good outlook on the speciality part of business,” he said.
Talking about Lupin, he said it is positive that they are developing their women healthcare portfolio